The Health Sciences Institute is intended to provide cutting-edge health information.
Nothing on this site should be interpreted as personal medical advice. Always consult with your doctor before changing anything related to your healthcare.

Drug Alert: Could new diabetes Rx be the worst one so far?

It’s only April’ and this is the third new dangerous diabetes drug I’ve already told you about this year. It’s hard enough figuring out how to beat diabetes without having to dodge all these risky new drugs!

The story said that this new diabetes drug is a “trailblazer.” But what it’s really doing is leaving a trail of pain and suffering.

And there’s no question that the risks of this recently approved Rx for type 2 far outweigh its benefits.

That is’ if there are any benefits at all…


The worst one of all?


It’s called Invokana’ and it’s a “special” kind of med in the same family as another newbie I warned you about in January. It lowers blood sugar by making your kidneys get rid of glucose through the urine.

And that can cause some serious side effects’ especially if you’re older.

In an attempt to stop Invokana’s approval’ Dr. Sidney Wolfe’ director of Public Citizen’s Health Research Group’ went before the FDA’s drug advisory committee last year. Dr. Wolfe presented evidence showing just how dangerous this drug will be for those with type 2.

He warned that the way the drug works’ by eliminating all that glucose in the urine’ “can cause a cascade of adverse events.” These include dehydration’ which can lead to low blood pressure’ dizziness and falls’ and damage to the kidneys and heart.

Even having “moderately” reduced kidney function’ he said’ puts people at high risk with this drug.

And the ones most at risk for failing kidneys — diabetics.

But that’s not all you would have to worry about when taking Invokana.

If you’re also on diuretics like Lasix and are over 75′ you would be in even greater danger of that “cascade” of side effects.

And what was the FDA’s reaction after hearing Dr. Wolfe’s comments?

It was to approve the drug only two months later!

But don’t think just because this risky med was given an official okay that the FDA didn’t know this drug could be very dangerous.

Wait till you hear what it told the drug’s maker’ Janssen Pharmaceuticals.

The FDA actually stated that its usual method of post market review of “adverse events” won’t be “sufficient” to learn if this drug poses a “serious risk” of cancers’ pancreatitis’ bone fractures’ liver damage’ hypersensitivity reactions and “adverse pregnancy outcomes.”

And that’s not the worst…

Instead of holding back until more is known about those risks’ the FDA said that it would be okay for Janssen to sell the drug’ but is “required” to be on the special lookout for all “foreign and domestic” reports of those horrible effects in patients taking Ivokana. And it was given until 2023 to submit a final report about it!

Do I have my math right here? You mean to tell me the plan is to tally up the damage toll for 10 years of diabetics taking this risky drug and then take another look?

And those heart dangers that Dr. Wolfe warned about — well the FDA has not “excluded the potential” of those risks either.

It ordered Janssen to complete a post-market double-blind trial with Invokana to see how many heart attacks’ strokes and fatalities it causes. And they have until 2017 to submit the report on that one.

Now the FDA might tell you that these dangers come with all prescription drugs. It’s that “risk vs. benefit” formula they are always talking about. But in this case’ it looks like there aren’t many benefits to add up’ either.

Dr. Wolfe’s group said that Invokana was approved without showing any “evidence of improvement in clinically meaningful outcomes.”

If there ever was any doubt that the FDA is more interested in helping Big Pharma than consumers’ its approval of Invokana should make that point loud and clear.

And by the time we get to 2023′ how many millions of us with type 2 diabetes will have been seriously harmed — or killed — by this drug while the FDA sits by waiting for the final report on its effects to come in?


“The new diabetes drug canagliflozin (INVOKANA)” Worst pills best pills newsletter’ February’ 2014′

Letter to Janssen Research & Development from the FDA’ NDA 204042′ March 29′ 2013′

Get a free copy of 5 Household Items that Cause Cancer

By texting HSI to 844-539-1128, you are providing your electronic signature expressly consenting to be called and texted (including by prerecorded messages, using an autodialer, and/or automated means) with alerts, stories, reports, and marketing communications from Institute of Health Sciences, LLC. and its authorized representatives at the phone number you provide, including landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also consent and unconditionally agree to our Privacy Policy and Terms of Use, including the arbitration provision and class action waiver contained therein. Msg&data rates may apply. 15 Msgs/Month. You are not required to agree to this as a condition of making a purchase.

Terms & Conditions

The following Terms and Conditions apply to your use of the website located at (the “website”) and any text messages that you send to or receive from the Institute of Health Sciences, L.L.C. These Terms and Conditions constitute a binding agreement (“Agreement”) between you (“you”) Institute of Health Sciences, L.L.C (“we”, “us”, etc.)  Please read these terms carefully. 

By providing your telephone number to us, texting us a short code listed on the website, or otherwise indicate your agreement to these Terms and Conditions, you are agreeing to the mandatory arbitration provision and class action waiver below. 


Text Messaging and Telemarketing Terms and Conditions

When you provide your telephone number on this website or send a text message to us with or from a short-code, you agree to receive alerts and communications, and marketing messages including those sent via automated telephone dialing system, text messages, SMS, MMS, and picture messages from Institute of Health Sciences, L.L.C at the phone number you provide on this website or the phone number from which you text the short code, including on landlines and wireless numbers, even if the phone number is on a corporate, state or national Do Not Call list. You also agree to the mandatory arbitration provision and class action waiver below. Your consent is not required to purchase goods or services. Message & data rates may apply.

You may opt-out at any time by texting the word STOP to the telephone number from which you receive the text messages.  Call 1-888-213-0764 to learn more.  By providing your telephone number, you agree to notify us of any changes to your telephone number and update your account us to reflect this change. Your carrier may charge you for text messages and telephone calls that you receive, or may prohibit or restrict certain mobile features, and certain mobile features may be incompatible with your carrier or mobile device. Contact your carrier with questions regarding these issues.

Dispute Resolution by Binding Arbitration and Class Action Waiver

Any dispute relating in any way to telephone calls, emails, or text messages that you receive from or on behalf of Institute of Health Sciences, L.L.C this website, or this Agreement (collectively “Disputes”) shall be submitted to confidential arbitration and shall be governed exclusively by the laws of the State of Maryland, excluding its conflict of law provisions.  For the avoidance of doubt, all claims arising under the Telephone Consumer Protection Act and state telemarketing laws shall be considered “Disputes” that are subject to resolution by binding individual, confidential arbitration.

If a Dispute arises under this Agreement, you agree to first contact us at 1-888-213-0764 or Before formally submitting a Dispute to arbitration, you and we may choose to informally resolve the Dispute.  If any Dispute cannot be resolved informally, you agree that any and all Disputes, including the validity of this arbitration clause and class action waiver, shall be submitted to final and binding arbitration before a single arbitrator of the American Arbitration Association (“AAA”) in a location convenient to you or telephonically. Either you or we may commence the arbitration process by submitting a written demand for arbitration with the AAA, and providing a copy to the other party.  The arbitration will be conducted in accordance with the provisions of the AAA’s Commercial Dispute Resolutions Procedures, Supplementary Procedures for Consumer-Related Disputes, in effect at the time of submission of the demand for arbitration.  Except as may be required by law as determined by the arbitrator, no party or arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of both parties. Institute of Health Sciences, L.L.C will pay all of the filing costs.  Without limiting the foregoing, YOU EXPRESSLY AGREE TO SUBMIT TO ARBITRATION ALL DISPUTES RELATING TO ANY TEXT MESSAGES OR TELEPHONE CALLS YOU RECEIVE FROM OR ON BEHALF OF US OR ANY ENTITY WITH WHOM WE MAY SHARE YOUR TELEPHONE NUMBER.  Further, we both agree that all entities with whom we share your telephone numbers shall be third party beneficiaries of this Agreement to Arbitrate Disputes, and that those entities have the same rights as Institute of Health Sciences, L.L.C to enforce this arbitration provision.

Notwithstanding the foregoing, the following shall not be subject to arbitration and may be adjudicated only in the state and federal courts of Maryland: (i) any dispute, controversy, or claim relating to or contesting the validity of our or one of our family company’s intellectual property rights and proprietary rights, including without limitation, patents, trademarks, service marks, copyrights, or trade secrets; (ii) an action by us for temporary or preliminary injunctive relief, whether prohibitive or mandatory, or other provisional relief; (iii) any legal action by us against a non-consumer; or (iv) interactions with governmental and regulatory authorities.  You expressly agree to refrain from bringing or joining any claims in any representative or class-wide capacity, including but not limited to bringing or joining any claims in any class action or any class-wide arbitration.

The arbitrator’s award shall be binding and may be entered as a judgment in any court of competent jurisdiction. To the fullest extent permitted by applicable law, no arbitration under this Agreement may be joined to an arbitration involving any other party subject to this Agreement, whether through a class action, private attorney general proceeding, class arbitration proceedings or otherwise.

YOU UNDERSTAND THAT YOU WOULD HAVE HAD A RIGHT TO LITIGATE IN A COURT, TO HAVE A JUDGE OR JURY DECIDE YOUR CASE AND TO BE PARTY TO A CLASS OR REPRESENTATIVE ACTION.  HOWEVER, YOU UNDERSTAND AND AGREE TO HAVE ANY CLAIMS DECIDED INDIVIDUALLY AND ONLY THROUGH ARBITRATION.  You shall have thirty (30) days from the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, to opt out of this arbitration agreement, by contacting us by email at or by mail Health Sciences Institute, PO Box 913, Frederick, MD 21705-0913. If you do not opt out by the earliest of the date that you visit the website, the date you submit information to us through the website, or the date that you send a text message to us, then you are not eligible to opt out of this arbitration agreement.

Electronic Signatures

All information communicated on the website is considered an electronic communication.  When you communicate with us through or on the website, by text message or telephone, or via other forms of electronic media, such as e-mail, you are communicating with us electronically.  You agree that we may communicate electronically with you and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communication.

You further acknowledge and agree that by clicking on a button labeled “ORDER NOW”, “SUBMIT”, “I ACCEPT”, “I AGREE”, “YES”, by texting a short code to us in response to a request on this website, or by clicking or similar links or buttons, you are submitting a legally binding electronic signature and are entering into a legally binding contract.  You acknowledge that your electronic submissions constitute your agreement and intent to be bound by this Agreement.  Pursuant to any applicable statutes, regulations, rules, ordinances or other laws, including without limitation the United States Electronic Signatures in Global and National Commerce Act, P.L. 106-229 (the “E-Sign Act”) or other similar statutes, YOU HEREBY AGREE TO THE USE OF ELECTRONIC SIGNATURES, CONTRACTS, ORDERS AND OTHER RECORDS AND TO ELECTRONIC DELIVERY OF NOTICES, POLICIES AND RECORDS OF TRANSACTIONS INITIATED OR COMPLETED THROUGH THE WEBSITE.  Furthermore, you hereby waive any rights or requirements under any statutes, regulations, rules, ordinances or other laws in any jurisdiction which require an original signature, delivery or retention of non-electronic records, or to payments or the granting of credits by other than electronic means You may receive a physical paper copy of this contract by contacting us at

Privacy Policy

Please read our Privacy Policy, which is incorporated herein by reference.  In the event of any conflict between these Terms and Conditions and the Privacy Policy, these Terms shall control.

Contact Us

You may contact us by telephone at 1-888-213-0764 or by email at